Market Access
Market Access for Innovators
The On-the-Ground Layer That Makes Market Entry Complete
Health-tech, biotech, and medtech innovators have proven solutions — but no map into the Meridian. Regulatory pathways, distribution networks, clinical evidence, and payor relationships each live in a different silo. That’s how we build — every market access capability stitched together into one integrated entry.
18–24 mo
Typical Regulatory Timeline Solo
30+
Decision-Makers Per Market (MoH, Payors, Systems)
0
Shortcuts Without On-Ground Experience
Four Capabilities
Four capabilities. One principle.
Innovative solutions only reach the Meridian patients when feasibility, regulation, distribution, and clinical evidence are integrated into one market entry. That’s Takamul applied to market access.
🔍
Feasibility Studies
Pre-entry market sizing, commercial pricing, and operational supply assessment
Integrated with local market intelligence to deliver a go/no-go investment recommendation before a single dollar is committed.
Market data + local insight + commercial reality = informed entry decisions
📋
Regulatory Pathways
SFDA, MOHAP, and DOH submissions, dossier remediation, GCC harmonisation, and fast-track routes
Integrated with in-country regulatory relationships to compress timelines.
Dossiers + regulatory relationships + local adaptation = faster approvals
🤝
Distribution & Commercial Partners
Distributor identification, hospital chain introductions, commercial deal structuring, and local entity setup
Integrated with regulatory status and market positioning to build routes-to-market that actually move product.
Partners + channels + deal structure = products on shelves
🏥
Clinical & Payor Pilots
Pilot design, real-world evidence generation, outcomes-based contracting, and reference-site case studies
Integrated with local clinical workflows and reimbursement models to create the evidence that unlocks adoption.
Pilots + evidence + payor buy-in = sustainable adoption
Integrated Impact
Integrated Impact Across Every Innovator
Each innovator type gets market access capabilities integrated into their specific context — not a generic advisory retainer.
Health-Tech & Digital Health
From pilot to national scale
Regulatory pathways for software-as-medical-device, payor pilot design for digital therapeutics, and distribution through health system IT procurement — integrated with clinical evidence generation to move from pilot to national scale.
Biotech & Pharmaceuticals
From registration through reimbursement
Dossier remediation, GCC harmonisation, and SFDA/MOHAP submissions — integrated with commercial partner identification and outcomes-based contracting to build market presence from registration through reimbursement.
MedTech & Devices
Sustainable commercial operations, not one-off sales
Hospital chain introductions, institutional procurement navigation, and clinical pilot design — integrated with local entity setup and after-sales support models to create sustainable commercial operations.
Diagnostics & Lab Solutions
Part of national health system priorities
Feasibility studies for lab infrastructure, regulatory submissions for IVDs, and distribution partner vetting — integrated with public health programme alignment to position diagnostics as part of national health system priorities.
How We Work
Your On-the-Ground Commercial Team
We don’t advise from a distance. We become your in-market commercial team — feasibility, regulatory, distribution, clinical pilots, all stitched together under one integrated engagement. You focus on the innovation. We deliver the market.
Differentiator 01
One Team, Not Five Vendors
Feasibility, regulatory, distribution, and evidence generation under one engagement — no handoffs, no coordination tax, no gaps between workstreams.
Differentiator 02
Success-Based, Not Retainer-Based
Our commercial model aligns with yours — we succeed when you launch, scale, and sustain. Not when we deliver a report.
Differentiator 03
Meridian-Native, Not Fly-In
Partners embedded across KSA, UAE, East Africa, West Africa, and South Asia — with the regulatory relationships and ministry access that only come from being on the ground.
Our Proof · Innovator Market Access
Lifecycle Market Access — From Entry to Scale
Three innovators. One playbook. Different sectors, different geographies — the same path: feasibility, regulatory and funding, distribution, then scale.
MedTech · India → Sub-Saharan Africa
Neonatal CPAP & resuscitation portfolio
Strong product, no Africa channel, no donor funding access. AMRA mapped donor funding routes, structured the case, negotiated distribution into Sub-Saharan markets, and stayed engaged through the revenue ramp.
Now — Scale & Revenue: multi-country presence with recurring donor-funded revenue.
HealthTech · Asia → Saudi Arabia
Real-time location systems for hospitals
Proven in Asia, no KSA presence. AMRA diagnosed the opportunity, structured the regulatory and partner pathway, and brokered hospital-chain introductions.
Now — Distribution: active KSA hospital deployment with a growing GCC pipeline.
HealthTech · United Arab Emirates
Clinical costing & analytics platform
Strong methodology, needed an anchor partnership. AMRA diagnosed UAE health-system fit and structured a partnership with a major UAE telecom, embedding analytics into a broader health-data offering.
Now — Regulatory & Funding: established in UAE via telecom partnership, first hospital deployments in pathway.
Ready to Enter the Meridian
Ready to Take Your Innovation Into the Meridian?
Partner with AMRA to integrate feasibility, regulation, distribution, and clinical evidence into one complete market entry — from first assessment to first patient.